Tyra Biosciences, Inc.
TYRA
$12.12
$0.4153.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.14M | 6.89M | 7.56M | 5.91M | 5.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.45M | 31.85M | 29.74M | 28.60M | 23.53M |
| Operating Income | -31.45M | -31.85M | -29.74M | -28.60M | -23.53M |
| Income Before Tax | -28.10M | -28.15M | -25.57M | -24.02M | -18.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.10M | -28.15M | -25.57M | -24.02M | -18.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.10M | -28.15M | -25.57M | -24.02M | -18.70M |
| EBIT | -31.45M | -31.85M | -29.74M | -28.60M | -23.53M |
| EBITDA | -31.31M | -31.71M | -29.60M | -28.48M | -23.41M |
| EPS Basic | -0.47 | -0.47 | -0.43 | -0.41 | -0.32 |
| Normalized Basic EPS | -0.29 | -0.30 | -0.27 | -0.25 | -0.20 |
| EPS Diluted | -0.47 | -0.47 | -0.43 | -0.41 | -0.32 |
| Normalized Diluted EPS | -0.29 | -0.30 | -0.27 | -0.25 | -0.20 |
| Average Basic Shares Outstanding | 59.55M | 59.34M | 59.06M | 58.87M | 58.67M |
| Average Diluted Shares Outstanding | 59.55M | 59.34M | 59.06M | 58.87M | 58.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |